I copied the following info from clinicaltrials.gov, ZEN-3694 trial 7 of 19. Not sure how to interpet the data - expansion cohorts A&B were discontinued based on results from an interim futility analysis - Parts 1 and 2 and Expansion Cohort C were completed. Overall study status was terminated.:
Study Overview
Brief Summary
This is a two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part 1 is a dose escalation and Part 2 is a Simon 2-Stage design. There are 3 expansion cohorts: Expansion Cohort A (combination treatment in post-TROP2-ADC patients), Expansion Cohort B (ZEN003694 monotherapy), and Expansion Cohort C (combination treatment in TROP2-ADC-naive patients).
Official Title
A Phase 2b Study of ZEN003694 in Combination With Talazoparib in Patients With Triple-Negative Breast Cancer
Parts 1 and 2 and Expansion Cohort C were completed. Expansion Cohorts A and B were discontinued based on results from an interim futility analysis and not due to safety concerns.
Study Status
First Submitted that Met QC Criteria
Last Update Submitted that Met QC Criteria
2024-05-03 [Actual]
??????Chicagoest
